Return to Listing

1 result(s) for

PI Name Protocol # Title
Bill Chang STUDY00020018 A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080